Managers / Q1 2022 · view latest →
Nextech Invest Ltd.
CIK 0001911010 · BAHNHOFSTRASSE 18, ZURICH, V8, CH-8001 · 41 (0)44 366 66 11
Summary
Nextech Invest Ltd. reported $350M in U.S.-listed holdings across 14 positions for Q1 2022.
The portfolio is heavily concentrated: RVMD alone accounts for 28.7% of reported value.
Compared with Q4 2021, the fund opened 3 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 82.5% · $289M
- Other · 17.5% · $61M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MRTXEURMIRATI THERAPEUTICS INC | NEW | +173.3K | 173.3K | +$14M | $14M |
| RLAYRELAY THERAPEUTICS INC | NEW | +475.5K | 475.5K | +$14M | $14M |
| 2655787DBLUEPRINT MEDICINES CORP | NEW | +188.2K | 188.2K | +$12M | $12M |
| EQRX INC | TRIMMED | −7.41M | 13.10M | −$86M | $54M |
| RVMDREVOLUTION MEDICINES INC | ADDED | +971.3K | 3.94M | +$26M | $100M |
| KNTEUSDKINNATE BIOPHARMA INC | HELD | +0 | 3.01M | −$19M | $34M |
| KRON1USDKRONOS BIO INC | HELD | +0 | 1.45M | −$9M | $10M |
| TYRATYRA BIOSCIENCES INC | HELD | +0 | 2.52M | −$8M | $27M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INChistory → | COM | 28.69% | $100M | 3.94M |
| 2 | EQRX INC | COM | 15.45% | $54M | 13.10M |
| 3 | KNTEUSDKINNATE BIOPHARMA INChistory → | COM | 9.67% | $34M | 3.01M |
| 4 | PMVPPMV PHARMACEUTICALS INChistory → | COM | 8.24% | $29M | 1.39M |
| 5 | TYRATYRA BIOSCIENCES INChistory → | COM | 7.69% | $27M | 2.52M |
| 6 | ARVNARVINAS INChistory → | COM | 5.52% | $19M | 287.3K |
| 7 | MRTXEURMIRATI THERAPEUTICS INChistory → | COM | 4.07% | $14M | 173.3K |
| 8 | RLAYRELAY THERAPEUTICS INChistory → | COM | 4.06% | $14M | 475.5K |
| 9 | CGEMCULLINAN ONCOLOGY INChistory → | COM | 3.65% | $13M | 1.22M |
| 10 | 2655787DBLUEPRINT MEDICINES CORPhistory → | COM | 3.43% | $12M | 188.2K |
| 11 | KRON1USDKRONOS BIO INChistory → | COM | 3.00% | $10M | 1.45M |
| 12 | CCCCC4 THERAPEUTICS INChistory → | COM STK | 2.60% | $9M | 375.9K |
| 13 | THESEUS PHARMACEUTICALS INC | COM | 2.01% | $7M | 611.3K |
| 14 | SPRYSILVERBACK THERAPEUTICS INChistory → | COM | 1.91% | $7M | 1.91M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $616M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $712M | 15 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $594M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $631M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $537M | 11 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $330M | 14 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $294M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $240M | 12 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $251M | 14 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $310M | 14 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $296M | 14 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $350M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $430M | 11 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.